相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET ONCOLOGY (2020)
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
Jonathan Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection
Peter C. Black et al.
CUAJ-Canadian Urological Association Journal (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial
Srikala S. Sridhar et al.
JAMA ONCOLOGY (2020)
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
Nick van Dijk et al.
EUROPEAN UROLOGY (2019)
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y. Fradet et al.
ANNALS OF ONCOLOGY (2019)
Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma
Mark Warren et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2019)
Management of metastatic bladder cancer
Rosa Nadal et al.
CANCER TREATMENT REVIEWS (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Jason Zhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Ashish M. Kamat et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth
Yijian Zhang et al.
CANCER LETTERS (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy
Kelly Kersten et al.
FRONTIERS IN IMMUNOLOGY (2015)
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2014)
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2013)
Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches
Richard M. Bambury et al.
FRONTIERS IN PHARMACOLOGY (2013)
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group
R Dreicer et al.
CANCER (2003)
分享论文
